Zacks Investment Management’s Cytokinetics CYTK Stock Holding History

Zacks Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,981	Closed	-$124K	–	530
2019 Q2	$124K	Sell	10,981 -7,757	-41%	-$74.8K	﹤0.01%	509
2019 Q1	$152K	Buy	+18,738	New	+$138K	﹤0.01%	512
2018 Q2	–	Sell	-16,868	Closed	-$121K	–	555
2018 Q1	$121K	Buy	+16,868	New	+$145K	﹤0.01%	499
2016 Q4	–	Sell	-25,787	Closed	-$237K	–	664
2016 Q3	$237K	Buy	+25,787	New	+$269K	0.01%	538
2015 Q3	–	Sell	-10,172	Closed	-$68K	–	603
2015 Q2	$68K	Buy	+10,172	New	+$66.7K	﹤0.01%	613

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Zacks Investment Management's CYTK Position: Q3 2019 in Review

Zacks Investment Management sold out of Cytokinetics (CYTK) in Q3 2019, closing a stake of 10,981 shares — an estimated $124K sold.

Zacks Investment Management first reported a position in CYTK in Q2 2015 and held it in 5 quarters. The position peaked at $237K in Q3 2016. 148 funds tracked by Wall St. Rank hold CYTK as of Q3 2019.

Zacks Investment Management reported no remaining Cytokinetics position as of Q3 2019 after selling out during the quarter.
Zacks Investment Management sold 10,981 Cytokinetics shares in Q3 2019, an estimated $124K.
Zacks Investment Management first reported a position in Cytokinetics in Q2 2015 and held it in 5 quarters.
Zacks Investment Management's Cytokinetics position peaked at $237K in Q3 2016.
148 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2019.

Based on Zacks Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.